We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Urinary Biomarker Found for Prostate Cancer Risk

By LabMedica International staff writers
Posted on 02 Nov 2010
A protein in urine could be a reliable marker for prostate cancer assessment and has advantages over the standard prostate specific antigen (PSA) test. More...


The protein, microseminoprotein-beta (MSMB), which is produced by normal prostate cells and secreted into urine from semen, regulates cell apoptosis or programmed cell death and is linked to an increased risk of developing prostate cancer.

In a multi-institute collaborative study, led by scientists from the Institute of Cancer Research, (CRUK; Cambridge, UK), tissue, urine and blood samples were analyzed from cohorts of prostate cancer patients. Urinary PSA and MSMB levels were determined by enzyme-linked immunoassays (ELISA) and normalized to creatinine. Samples from 133 of the patients were made into a tissue microarrays (TMA) containing multiple cores from normal/benign regions (>3), prostatic intraepithelial neoplasia (PIN) and at least two distinct regions of tumor for each patient. Genotyping was performed on DNA extracted from blood samples.

The urinary levels of MSMB were determined in 215 men with no history of prostate disease and 89 men with prostate cancer. Consistent with the association in prostate tissue there was a significant decrease in urinary MSMB in men with tumors compared with men with no history of prostate disease. No normal or tumorigenic tissues demonstrated any MSMB staining suggesting that at the protein level in tissue MSMB is highly prostate specific. In particular the tissues surrounding the prostate, such as urothelium, seminal vesicles and bladder muscularis propria layer showed no staining whereas adjacent benign prostate glands were heavily stained. MSMB demonstrated high levels of specificity and sensitivity particularly when compared to urinary PSA. There was a significant decrease in urinary MSMB with the high risk allele compared to the low risk allele.

Hayley Whitaker, Ph.D., the lead author, said, "Microseminoprotein-beta (MSMB), is easy to detect because it is found in urine and would potentially be a very simple test to carry out on men to identify those most at risk". The study was published on line on October 13, 2010, in the open access journal from the Public Library of Science, PLoS One.

Related Links:
Institute of Cancer Research



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.